Arvinas, Inc - ARVN STOCK NEWS

Insilico Medicine has announced a strategic R&D collaboration with Arvinas (NASDAQ: ARVN), focusing on integrating artificial intelligence with PROTAC technology for drug development. This partnership aims to design innovative treatment modalities for various targets, leveraging AI's potential in drug discovery. Insilico has also recently completed a $255 million funding round and nominated its second preclinical candidate for kidney fibrosis. This collaboration signifies a pivotal move in the biotech sector, enhancing the capabilities of both companies in developing transformative therapeutics.

Arvinas, Inc. (Nasdaq: ARVN) reported Q2 2021 financial results, showing a net loss of $50.3 million compared to $25.2 million a year earlier. The company announced a collaboration with Pfizer for its PROTAC degrader ARV-471, receiving an upfront payment of $650 million and a $350 million equity investment. R&D expenses increased to $43 million, while revenue slightly decreased to $5.5 million. As of June 30, 2021, cash and marketable securities totaled $605.1 million. Key milestones include upcoming Phase 1 trial data presentations for ARV-471 and ARV-110.

Arvinas and Pfizer have formed a global collaboration to develop ARV-471, an investigational breast cancer therapy currently in Phase 2 development for ER+/HER2- patients. The agreement includes a $650 million upfront payment from Pfizer, alongside a $350 million equity investment in Arvinas, granting Pfizer approximately 7% ownership. Profit and cost sharing will be 50/50 worldwide, with potential milestone payments reaching $1.4 billion. This partnership aims to leverage Pfizer's oncology expertise to enhance the commercial potential of ARV-471.

Arvinas, Inc. (Nasdaq: ARVN) announced a groundbreaking ceremony for a new 525,000-square-foot building at 101 College Street in New Haven, scheduled to serve as its headquarters starting in 2024. The company will occupy around 160,000 square feet, promoting its growth and contributing to the local biopharmaceutical sector. The construction project is part of New Haven's Downtown Crossing initiative, funded by various public entities, aimed at revitalizing the area and enhancing connectivity within the life sciences district.

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced participation in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 10 at 10:30 a.m. ET. Chief Medical Officer Ron Peck, M.D., and Chief Financial Officer Sean Cassidy will engage in a fireside chat. The event will be available via live audio webcast on Arvinas’ website, with a replay accessible for 30 days. Arvinas focuses on developing therapies that target and degrade disease-causing proteins using its innovative PROTAC® technology.

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, has announced that John Houston and Ian Taylor will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. The event will be available via a live audio webcast and archived for 30 days on Arvinas' website. Arvinas aims to improve patient lives by developing therapies that degrade disease-causing proteins, with two clinical-stage programs: ARV-110 for prostate cancer and ARV-471 for breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) announced plans to lease approximately 160,000 square feet at 101 College Street in New Haven, Connecticut. This move will facilitate the company’s continued growth in the biopharmaceutical sector, particularly in its efforts to develop targeted protein degradation therapies. The new facility is expected to be complete and ready for occupancy by 2024. This decision is seen as a testament to Arvinas' commitment to the local economy and its ongoing partnership with Yale University.

Arvinas, Inc. (Nasdaq: ARVN) reported its Q1 2021 financial results, revealing a net loss of $41 million, up from $21.7 million in Q1 2020. Revenues decreased to $5.5 million from $6.2 million, impacted by a collaborator's extended revenue recognition period. R&D expenses rose to $34.9 million, primarily due to ongoing platform investments. Arvinas maintains a strong cash position of $651.3 million, expected to fund operations into 2024. Key milestones include anticipated data presentations for ARV-110 and ARV-471 in 2021, reinforcing its leadership in targeted protein degradation.

On April 5, 2021, Arvinas, a clinical-stage biotechnology company, announced two presentations at the AACR Annual Meeting 2021, focusing on its PROTAC degraders, ARV-110 and ARV-471. These presentations will be held virtually from April 10-15, 2021, and May 17-21, 2021.

ARV-110 targets metastatic castration-resistant prostate cancer, while ARV-471 is aimed at ER+/HER2- breast cancer. Both presentations are scheduled for April 11, 2021, delivered by Dr. Lawrence B. Snyder. Abstracts will be available on the AACR website starting April 9, 2021.